Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › latanoprost

latanoprost

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of latanoprost

6 trials tracked of latanoprost: 2 in phase 3 or 4.

6Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 3 Other / NA 1
  1. Phase 4 The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye Completed
  2. Phase 3 A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma. Completed
  3. Phase 2 Circadian Rhythms of Aqueous Humor Dynamics in Humans Completed
  4. Phase 2 A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 Completed
  5. Phase 2 Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension Completed
  6. N/A Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Comparative Efficacy and Safety of Preservative-Free versus Preserved Latanoprost for Glaucoma
Ophthalmology Meta-analysis
Comparative Efficacy and Safety of Preservative-Free versus Preserved Latanoprost for Glaucoma Preservative-Free Latanoprost Cuts Eye Redness Risk
A meta-analysis of 1880 eyes compares preservative-free latanoprost to preserved versions, evaluating IOP reduction and ocular surface safet…
A new analysis finds preservative-free latanoprost lowers eye redness risk by 34% while matching standard drops' pressure control after 4 we…
Jul 5, 2026
Netarsudil plus latanoprost cuts diurnal IOP 2.36 mmHg vs latanoprost alone in Japanese glaucoma
Ophthalmology RCT
Netarsudil plus latanoprost cuts diurnal IOP 2.36 mmHg vs latanoprost alone in Japanese glaucoma Adding netarsudil to latanoprost lowers eye pressure faster in Japanese patients with glaucoma
This Phase III randomized controlled trial in 246 Japanese participants with primary open-angle glaucoma or ocular hypertension found that n…
Japanese patients with glaucoma saw lower eye pressure when adding netarsudil to their current latanoprost drops compared to a placebo plus …
Jun 1, 2026
Netarsudil shows lower IOP reduction but better conjunctival hyperemia profile versus prostaglandin analogues
Ophthalmology Meta-analysis
Netarsudil shows lower IOP reduction but better conjunctival hyperemia profile versus prostaglandin analogues New data shows netarsudil offers a safer option for some glaucoma patients
A Bayesian network meta-analysis found netarsudil ranked lower for IOP reduction but had a more favorable conjunctival hyperemia profile com…
A fresh look at glaucoma drugs shows one option causes less redness while still helping lower eye pressure effectively.
May 14, 2026